Medscape

Decipher Scores Help Predict Upgrade on PCa Active Surveillance

Decipher test scores are independently associated with biopsy upgrades in men on active surveillance for Gleason grade group 1 prostate cancer. Higher Decipher scores on the initial test are ...
Medscape

Genetic Test Helps Predict PCa Progression on Active Surveillance

The Decipher Prostate genomic classifier — a genomic test performed on biopsy samples to gauge the expression of 22 genes involved in prostate cancer progression — was associated with Gleason ...
Nasdaq

New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer

Findings from ancillary study of Phase 3 STAMPEDE trial reveal Decipher Prostate test is prognostic for clinical outcomes in men with high-risk non-metastatic and metastatic prostate cancer Data ...
News Medical

Decipher Prostate Cancer Classifier predicts metastasis in patients treated with salvage radiation therapy

GenomeDx Biosciences today announced that data presented at the 2015 American Society of Clinical Oncology Annual Meeting demonstrate that the Decipher® Prostate Cancer Classifier is a significant ...
Business Wire

New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced that new data published in European Urology Oncology suggest the Decipher Prostate Genomic Classifier could help ...
Healio

Decipher test predicts metastasis risk following radical prostatectomy

Please provide your email address to receive an email when new articles are posted on . The genomic classifier test Decipher independently improved prognostication over clinicopathologic variables for ...
Business Wire

Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that its Decipher ® Prostate RP genomic classifier is uniquely recommended in the 2022 National ...
Seeking Alpha

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the launch of its Decipher Prostate Metastatic Genomic ...
ascopubs.org

Decipher Postprostatectomy: Is It Ready for Clinical Use?

Can Genomic Data Guide the Postoperative Management of Prostate Cancer? Finally, observing the primary end point of metastasis may have been subject to ascertainment bias. 14 Specifically, whereas ...
Seeking Alpha

Veracyte: Investing In The Future Of Genomic Diagnostics

With its range of products, Veracyte displays a robust and diverse portfolio, targeting multiple areas in oncology. Veracyte's recent data underscores the company's innovative edge in the field of ...
Nasdaq

New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification

Findings published in European Urology Oncology suggest genomic classifier scores are highly correlated with PSMA PET upstaging of prostate cancer in those with high-risk and very high-risk disease ...